Jo Anne Zujewski

Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

Edith A. Perez, Edward H. Romond, Vera J. Suman et al. · Journal of Clinical Oncology · 2014 · 998 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Martine Piccart, Eileen Holmes, José Baselga et al. · Journal of Clinical Oncology · 2015 · 374 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses

Jung Min Lee, John L. Hays, Christina M. Annunziata et al. · JNCI Journal of the National Cancer Institute · 2014 · 183 citations · Full text

Medicine, Oncology, Pharmacology +14

First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).

Martine Piccart, Andrew Holmes, José Baselga et al. · Journal of Clinical Oncology · 2014 · 144 citations

Medicine, Oncology, Pharmacology +17

Exploring stigma as a barrier to cancer service engagement with breast cancer survivors in Kampala, Uganda

Elizabeth Meacham, Jackson Orem, Gertrude Nakigudde et al. · Psycho-Oncology · 2016 · 101 citations · Full text

Medicine, Oncology, Breast Oncology +16